Previous 10 | Next 10 |
Nanobiotix (NBTX) announces data from its early-stage trial of its NBTXR3 combination in patients with certain advanced forms of cancer, to be presented at the American Society for Clinical Oncology ((ASCO)) conference.The trial for patients with advanced cancers treated with an anti-PD-1 the...
Data to be Presented at the 2021 Annual Meeting of the American Society for Clinical Oncology Results show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into responders Objective response was observed in 60% o...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
Nanobiotix (NBTX) announces the appointment of Bart Van Rhijn as chief financial officer and member of the company’s executive board.He succeeds Philippe Mauberna, who will step down from his roles after 8 years of service.Bart Van Rhijn brings extensive experience ...
Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, tod...
Nanobiotix (NBTX) announces that Gary Phillips has been appointed as the new chairman of the company’s supervisory board.He succeeds Laurent Condomine, who will retire from the supervisory board after 11 years in the role.Phillips, who is currently president and chief executi...
Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, tod...
Updated results from phase I dose expansion in head and neck cancer showed durable signs of efficacy at a median follow up of 8.1 months, with an overall objective response rate of 82.5% and a complete response rate of 62.5% 1 Data from the expansion part of the study continue...
Updated results from phase I dose expansion in head and neck cancer showed durable signs of efficacy at a median follow up of 8.1 months, with an overall objective response rate of 82.5% and a complete response rate of 62.5% Data from the expansion part of the study continue to su...
Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, tod...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...